Section 8, Obesity Management for the Treatment of Type 2 Diabetes, of the Standards of Medical Care in Diabetes—2020 has been annotated based on a U.S. Food and Drug Administration Drug Safety Communication.

The online version of the article (https://doi.org/10.2337/dc20-S008) reflects the changes described below.

Updates have been made to the “Approved Weight-Loss Medications” subsection (p. S92).

The following sentence was revised to change “Five” to “Four”:

“Four weight-loss medications are FDA approved for long-term use (more than a few weeks) by patients with BMI ≥27 kg/m2 with one or more obesity-associated comorbid condition (e.g., type 2 diabetes, hypertension, and/or dyslipidemia) who are motivated to lose weight (46).”

The following sentence was added:

“The FDA requested the withdrawal of weight-loss drug lorcaserin (U.S. Food and Drug Administration, 2020); it should no longer be used.”

Table 8.2:

“Lorcaserin” has been removed from Table 8.2.

U.S. Food and Drug Administration
.
FDA requests the withdrawal of the weight-loss drug Belviq, Belviq XR (lorcaserin) from the market
.
Potential risk of cancer outweighs the benefits. 13 February 2020 [FDA Drug Safety Communication]. Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-requests-withdrawal-weight-loss-drug-belviq-belviq-xr-lorcaserin-market
© 2020 by the American Diabetes Association
2020
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/content/license.